Status:
COMPLETED
A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Diabetes Mellitus Type 2
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This 2 arm study will compare the effects of aleglitazar and Actos, added to preexisting oral antihyperglycemic therapy and/or diet and exercise, on renal function in patients with type 2 diabetes, an...
Eligibility Criteria
Inclusion
- adult patients, 18-75 years of age;
- type 2 diabetes for \>=1 month;
- drug naive, or receiving stable oral antihyperglycemic medication;
- HbA1c 6.5-10.0% at screening.
Exclusion
- type 1 diabetes;
- current or previous treatment with insulin;
- history of renal disease other than diabetic nephropathy;
- uncontrolled hypertension;
- clinically significant cardiovascular disease;
- Congestive heart failure (CHF) New York Heart Association (NYHA) 3-4.
Key Trial Info
Start Date :
June 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
176 Patients enrolled
Trial Details
Trial ID
NCT00461006
Start Date
June 1 2007
End Date
September 1 2008
Last Update
August 1 2016
Active Locations (52)
Enter a location and click search to find clinical trials sorted by distance.
1
Peoria, Arizona, United States, 85381
2
Jonesboro, Arkansas, United States, 72401
3
Fresno, California, United States, 93720
4
Los Gatos, California, United States, 95032